Metagenomi Therapeutics, Inc.
In the quarter to June 2026, revenue fell 103.0%, EPS fell 35.2% and free cash flow grew 7.98%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow MGX
Metagenomi Therapeutics, Inc. (MGX) EV/Sales
As of 16 October 2026, Metagenomi Therapeutics, Inc. (MGX) trades at a EV/Sales of −4.5×. Over the past ten years it has ranged from −4.7× (June 2024) to −0.9× (October 2025); the current reading is higher than 4% of that period. That is below the Biotechnology industry median of 9.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | −2.8× | — |
| FY2024 | −1.9× | — |
| FY2023 | −4.6× | — |
| FY2022 | −4.6× | — |
| FY2021 | −4.6× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | −3.4× | — |
| Mar 2026 | −2.7× | — |
| Dec 2025 | −2.8× | — |
| Sep 2025 | −2.1× | — |
| 10 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| MGX Metagenomi Therapeutics, Inc. | −4.5× |
| ATNM Actinium Pharmaceuticals, Inc. compare | 0.0× |
| RNAZ TransCode Therapeutics Inc. compare | n/m |
| BCTX BRIACELL THERAP compare | n/m |
| GRDX GridAI Technologies Corp. compare | n/m |
| GNTA Genenta Science S.p.A. Unsponsored ADR compare | n/m |
| NXTC NextCure, Inc. compare | 0.6× |
| ALGS Aligos Therapeutics, Inc. compare | 0.6× |
| CVM Cel-Sci Corporation compare | 35.0× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)